Supriya Lifescience Ltd.

NSE: SUPRIYA | BSE: 543434 | ISIN: INE07RO01027 | Industry: Pharmaceuticals
| Expensive Performer
645.8500 -14.05 (-2.13%)
NSE Mar 20, 2025 15:31 PM
Volume: 212.4K
 

645.85
-2.13%
KRChoksey
For Q3FY24, SUPRIYA’s revenue grew by 33.2% YoY and stayed flat for QoQ at INR 1,401 Mn, while for 9MFY24, revenue grew by 29.3% YoY to INR 4,122 Mn. The Q3FY24 revenue growth was driven by analgesic/anti-pyretic/anaesthetic (49.0% of revenue in Q3FY24, +157.8% YoY), vitamin (14.0% of revenue, +14.0% YoY) and Anti-malarial (2.0% of revenue, +28.9% YoY), which was partially offset by anti-asthma (7.0% of revenue, -50.5% YoY), anti-Histamine (15.0% of revenue, -27.1% YoY) and anti-allergic (5.0% of revenue, -36.8% YoY). Geographically, Europe (42.0% contribution to Q3FY24 revenue vs 26.0% in Q3FY23) led the top-line momentum; Asia’s revenue contribution decreased to 42.0% from 50.0% in Q3FY23.
Supriya Lifescience Ltd. has gained 99.52% in the last 1 Year
More from Supriya Lifescience Ltd.
Recommended